Section 10(b) and Rule 10b-5 class actions are federal court cases, governed by the heightened pleading standard of the Private Securities Litigation Reform Act. We file fewer cases, we file them cleaner, and we hold them to that standard.
Attorney Advertising. Prior results do not guarantee a similar outcome.
A federal securities class action under Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 is a lawsuit brought on behalf of all investors who purchased or sold shares of a public company during a defined period in which the company allegedly made material misrepresentations or omissions about its business, finances, or prospects.
When the truth comes out — through a corrective disclosure, an SEC enforcement action, a press release, an analyst report, or a triggering event like an accounting restatement — the share price typically declines, and shareholders who bought during the misrepresentation period suffer a loss. That loss may be recoverable.
There is also a separate set of claims under Section 11 and Section 12 of the Securities Act of 1933, which apply to misrepresentations and omissions in registration statements and prospectuses for IPOs, secondary offerings, and other registered securities offerings. Section 11 claims do not require proof of scienter and operate on a different liability framework.
Amparo Investor Rights handles both Exchange Act §10(b) and Securities Act §§11/12 cases.
To survive a motion to dismiss in a federal securities class action, a complaint must plausibly allege six elements, with the fraud-specific elements pleaded with the particularity required by Federal Rule 9(b) and the PSLRA:
Material misrepresentation or omission. A statement or omission that a reasonable investor would consider important in deciding whether to buy or sell securities.
Scienter. A mental state demonstrating either intent to deceive or recklessness so severe that it approaches conscious disregard for the truth.
Connection to the purchase or sale of a security. The misrepresentation must relate to the purchase or sale of a covered security.
Reliance. Either direct (presumed under the fraud-on-the-market doctrine for actively traded stocks) or pleaded specifically.
Economic loss. The plaintiff must have suffered an actual loss.
Loss causation. The misrepresentation, not other market or business factors, must have caused the loss.
The PSLRA’s heightened pleading standard is one of the most aggressive procedural barriers in federal civil practice. Tellabs v. Makor Issues & Rights requires a complaint to plead facts giving rise to a “strong inference” of scienter — an inference at least as compelling as any nonculpable explanation for the conduct. We approach scienter pleading the way a federal-court-trained advocate has to: facts, not adjectives.
The following events are common starting points for a 10b-5 investigation:
A company restates prior-period financials — revenue recognition, expense classification, or impairment errors — often suggesting prior statements were materially false when issued.
An SEC enforcement action against a company or its officers creates a record of misconduct that supports private litigation under Section 10(b).
A former employee, executive, or auditor publicly raises allegations of accounting fraud, channel stuffing, or sales misreporting that materially misstated financials.
A drug fails Phase III after positive interim data; a device fails 510(k) clearance after a projected approval; a SaaS company loses a major contract after touting its pipeline.
A ransomware attack or data breach the company had previously disclaimed in risk factors, or where disclosure was deficient under SEC Item 106 cyber rules.
A merger collapses after the company touted synergy, integration progress, or regulatory clearance.
The auditor resigns, raises a disclaimer, or issues a going-concern qualification — events that frequently signal undisclosed problems with revenue, controls, or solvency.
These triggers are not exhaustive. Every investigation we open begins with primary-source review of the company’s filings, its publicly available statements, the share-price reaction, and the relevant market and regulatory context.
The PSLRA created a structured “lead plaintiff” appointment process unique to federal securities class actions. Within 60 days of the first-filed complaint or the announcement of the action in a national business-oriented publication, any class member may move to be appointed lead plaintiff.
The PSLRA establishes a presumption that the most adequate plaintiff is the movant who has filed a complaint or moved for appointment, has the largest financial interest in the relief sought, and otherwise satisfies Rule 23 of the Federal Rules of Civil Procedure.
For institutional investors — pension funds, endowments, family offices, insurance companies — the PSLRA was specifically designed to encourage your participation. Institutions often have the largest financial interest among class members and are well-positioned to satisfy Rule 23 typicality and adequacy.
For individual investors — retail investors with significant losses can also serve as lead plaintiff, sometimes through aggregation with other investors. We advise on whether and how to file a lead plaintiff motion based on your holdings, the size of your loss, and the procedural posture of the case.
We charge no fee for the lead plaintiff motion or the underlying representation.
Sections 11 and 12 of the Securities Act of 1933 provide separate causes of action arising from material misrepresentations or omissions in registration statements and prospectuses. These claims:
When a recently-IPO’d company experiences a sharp share-price decline traceable to material disclosure issues in the registration statement, Section 11 is the preferred vehicle. We have handled traceability discovery and standing analysis for Section 11 cases and approach this category as distinct from Exchange Act §10(b) work.
We review filings, share-price reaction, public statements, and the regulatory record. We may issue a press release announcing the investigation.
Class members move to be appointed lead plaintiff. Court selects within ~30–60 days.
Lead plaintiff files an amended consolidated complaint.
Defendants typically move to dismiss; this is the heart of the PSLRA pleading test.
If the case survives the motion to dismiss, discovery proceeds and the court rules on class certification.
Most cases settle. Trial is rare but available.
These ranges are typical, not guaranteed. Federal securities class actions can move faster or slower depending on docket congestion, motion practice, and the complexity of the underlying allegations.
Many shareholder firms file rapid-fire complaints to position for lead plaintiff. We don't. We open an investigation, review primary sources, and file when we believe a complaint can survive a motion to dismiss under the PSLRA. When the facts won't support that, we don't file.
Securities class actions reward depth of bench. Where appropriate, we coordinate with experienced shareholder co-counsel on PSLRA pleading, class certification strategy, and trial readiness. The firm's securities of-counsel relationship is disclosed in writing in every retainer agreement.
Scienter is the most common dismissal basis in §10(b) cases. We invest the time to develop a scienter narrative that is specific, plausibly pleaded, and resilient to Tellabs attack — facts about who knew what and when, drawn from filings, executive sales, and corroborating sources.
No out-of-pocket cost to you. We advance all expenses. Fees come out of any recovery, on terms set out in writing.
A securities class action is a federal-court lawsuit brought on behalf of all investors who bought or sold shares of a publicly traded company during a defined “class period” — a stretch of time when the company allegedly made material misrepresentations or omissions about its business. The most common basis is Section 10(b) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. When the truth comes out and the share price drops, investors who bought during the class period may have a recoverable loss. Cases are governed by the heightened pleading standard of the PSLRA.
Under the PSLRA, the court appoints a lead plaintiff from among investors who file a motion within 60 days of the first published notice of the case. The PSLRA creates a rebuttable presumption that the investor (or institutional group) with the largest financial interest in the relief sought, who otherwise satisfies Rule 23, is the most adequate plaintiff. Most lead plaintiffs are institutional investors, but qualified individual investors can and do serve.
The PSLRA 60-day clock starts the day notice of the case is published — typically in a national wire-service announcement on the date the first complaint is filed. Missing the 60-day deadline forecloses your ability to seek lead-plaintiff status in that case, though you can still recover as an absent class member if a class is later certified. Lead plaintiff deadlines for every active investigation we track are posted on our Active Investigations page.
Nothing up front. Securities class actions are litigated on contingency: our firm advances all expenses, and fees are paid only out of any recovery, subject to court approval under Federal Rule 23(h). You do not pay legal fees out of pocket and you do not pay anything if there is no recovery. Exact fee terms are set out in our engagement letter at the time we are retained.
No. Absent class members — investors who never file anything — typically recover automatically once a class is certified and a settlement or judgment is reached. You file a claim form against the settlement fund and receive a pro-rata share based on the per-share loss allowed by the court-approved Plan of Allocation. Filing a claim form is not the same as filing a lawsuit.
A class action seeks recovery directly for the shareholders who bought during the class period — damages flow to investors. A derivative action is brought on behalf of the corporation itself against its directors or officers for breach of fiduciary duty; recovery goes to the corporate treasury, and shareholders benefit indirectly. They address different harms and can sometimes coexist. We litigate both.
If you purchased shares during the defined class period in the complaint — and especially if you held through the corrective disclosure event — you are likely a class member. The class definition is set in the complaint and refined when the court certifies a class under Rule 23. Our free portfolio monitoring service cross-references your historical holdings against active securities investigations.
Securities class actions are not fast. Most move through three phases: (1) motion to dismiss — typically 12 to 24 months after the lead-plaintiff order, given the PSLRA automatic discovery stay; (2) class certification and merits discovery — another 12 to 24 months; (3) summary judgment, trial, or settlement — typically resolved 3 to 5 years from filing in total.
You may still be a class member. Class periods cover both purchases and sales — what matters is whether your transactions occurred during the defined class period and whether you suffered a recoverable loss under the Plan of Allocation. Keep your brokerage statements and trade confirmations; we use them to compute your recoverable loss when a claim form is filed.
Institutional investors are well-positioned to serve as lead plaintiffs under the PSLRA because of the largest-financial-interest presumption. Beyond fiduciary considerations under ERISA or state law, lead-plaintiff service gives institutions a direct seat in case strategy, settlement negotiations, and selection of class counsel. We work with public pension funds, Taft-Hartley funds, endowments, foundations, and registered investment advisers.
securities CA
NASDAQ: TSRA · Class period Mar–Aug 2025
Bind this rail to the Investigation CPT filtered to investigation_type = securities_class_action, capped at 2–3. If the loop returns zero, hide this block via Elementor display condition rather than showing the heading over an empty rail. Sample card shown for layout only.
Tell us your holdings; we flag you when an investigation matches a class period. Free. No obligation.
Free, confidential consultation. We tell you straight whether you have a case.